Skip to main content
PLOS One logoLink to PLOS One
. 2021 Feb 5;16(2):e0245994. doi: 10.1371/journal.pone.0245994

Association between Toxoplasma gondii seropositivity and serointensity and brain volume in adults: A cross-sectional study

Lance D Erickson 1, Bruce L Brown 2, Shawn D Gale 2,3,*, Dawson W Hedges 2,3
Editor: Niels Bergsland4
PMCID: PMC7864421  PMID: 33544748

Abstract

The intracellular protozoal parasite Toxoplasma gondii has been associated with worsened cognitive function in animal models and in humans. Despite these associations, the mechanisms by which Toxoplasma gondii might affect cognitive function remain unknown, although Toxoplasma gondii does produce physiologically active intraneuronal cysts and appears to affect dopamine synthesis. Using data from the UK Biobank, we sought to determine whether Toxoplasma gondii is associated with decreased prefrontal, hippocampal, and thalamic gray-matter volumes and with decreased total gray-matter and total white-matter volumes in an adult community-based sample. The results from adjusted multivariable regression modelling showed no associations between Toxoplasma gondii and prefrontal, hippocampal, and thalamic brain gray-matter volumes. In contrast, natural-log transformed antibody levels against the Toxoplasma gondii p22 (b = -3960, 95-percent confidence interval, -6536 to -1383, p < .01) and sag1 (b = -4863, 95-percent confidence interval, –8301 to -1425, p < .01) antigens were associated with smaller total gray-matter volume, as was the mean of natural-log transformed p22 and sag1 titers (b = -6141, 95-percent confidence interval, -9886 to -2397, p < .01). There were no associations between any of the measures of Toxoplasma gondii and total white-matter volume. These findings suggest that Toxoplasma gondii might be associated with decreased total gray-matter in middle-aged and older middle-aged adults in a community-based sample from the United Kingdom.

Introduction

Infecting approximately one-third of the world’s population [1], the neurotropic intracellular apicomplexan protozoal parasite Toxoplasma gondii can remain in the brain for the life of the host [2]. The definitive hosts for Toxoplasma gondii are members of the cat family, which release oocysts into the environment, from where they can infect humans via contact with cat feces, ingestion of undercooked meat containing Toxoplasma gondii oocysts, or congenital transmission [3].

Some research fails to identify associations of Toxoplasma gondii seropositivity and serointensity with cognitive impairment [46], and one study even found an association between Toxoplasma gondii and better action control and smaller P300 event-related potential, which could indicate better cognitive function in certain cognitive tasks [7]. However, several studies have found associations between Toxoplasma gondii and impaired cognitive function [814]. One recent study using data from the UK Biobank found that Toxoplasma gondii was associated with worse executive function in adults, even after adjusting for several potentially confounding variables [15]. Furthermore, meta-analyses have identified associations of Toxoplasma gondii with dementia [16] and epilepsy [17]. Finally, in a sample of older adults, participants seropositive for Toxoplasma gondii had worse working memory, smaller P3b amplitude with event-related potentials, and reduced evoked frequency in the theta range compared to seronegative participants [18]. Together, these findings suggest that Toxoplasma gondii might be adversely associated with brain function.

Despite mounting evidence suggesting that Toxoplasma gondii adversely affects brain function in humans, the mechanisms underlying these associations remain unknown, although findings suggest several possible indirect mechanisms. Among potential indirect mechanisms, Toxoplasma gondii can increase the permeability of the gastrointestinal-blood barrier [2], which could enable increased toxin entry into the blood and from there into the brain. In addition, Toxoplasma gondii forms intraneuronal cysts that appear to be metabolically active [19], possibly affecting brain dopamine, glutamate, gamma amino butyric acid, and serotonin [20], neurotransmitters that could affect cognitive and brain function. Toxoplasma gondii also appears to affect gene expression [21]. Therefore, there are several possible mechanisms through which Toxoplasma gondii could affect brain function, potential mechanisms that could operate simultaneously.

Given the associations between Toxoplasma gondii and evidence of adverse effects on brain function and potential mechanisms by which it could affect neuronal function, Toxoplasma gondii could be related to adverse brain and cognitive functioning by affecting brain volume. Brain volume is weakly but consistently associated with cognitive function including intelligence [22]. In a community-based sample, brain volume in later life was concurrently associated with cognitive function [23]. To date, however, only a few studies have investigated associations between Toxoplasma gondii and brain volume. In a murine model, mice infected with Toxoplasma gondii for at least a year after initial infection in early adulthood had increased ventricular volume and elevated markers of neuron death [24]. In humans, a voxel-based morphometry study of 44 participants with schizophrenia and 56 healthy controls [25] found an association between Toxoplasma gondii and decreased gray-matter density among the participants with schizophrenia but not in the control participants.

Based on findings of possible adverse brain function including cognition associated with Toxoplasma gondii and preliminary evidence that it might alter brain volume, we sought to investigate further whether Toxoplasma gondii might be associated with brain volume using a larger sample than that used in the previously reported study [25], hypothesizing that Toxoplasma gondii would be associated with reduced brain volume. To test this hypothesis, we used a community-based dataset from the UK Biobank of middle and late middle-aged adults that contains data describing infection with Toxoplasma gondii, volumetric magnetic resonance imaging data, and demographic data (http://www.ukbiobank.ac.uk).

Methods

Study sample

The participants in this study are from the UK Biobank, a community-based sample of about 500,000 adults enrolled at ages 40 to 69 years between 2006 and 2010 and sampled from population-based registries (http://www.ukbiobank.ac.uk) [26]. In this database, there were 21,402 participants who had magnetic resonance brain imaging data (UK Biobank Brain Imaging Documentation, http://www.ukbiobank.ac.uk) and 9,431 participants who had serological data for exposure to Toxoplasma gondii. Only 434 participants, however, were eligible for our analyses in that they had both magnetic resonance imaging data and serological data for Toxoplasma gondii. Our final analytic sample was 385 due to missing data on our preidentified control variables. Although the UK Biobank sample is not representative of the UK population, the dataset can still be used to establish valid exposure-outcome associations (http://www.ukbiobank.ac.uk/wp-content/uploads/2017/03/access-matters-representativeness-1.pdf). The UK Biobank received ethical approval to collect demographic and medical data (reference 11/NW/0382), and all participants provided informed consent (http://biobank.ctsu.ox.ac.uk/crystal/field/cgi?id=200). We received regulatory approval from the UK Biobank to use data from the UK Biobank for our research (http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=200).

Brain volumes

We used pre-processed magnetic-resonance brain imaging data that the UK Biobank had obtained between 30 April 2014 and 19 March 2019 acquired using a 3-Tesla, 32-channel coil Siemens Skyra scanner (Siemens Medical Solutions, Germany; http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=100003) [27, 28]. In our analyses, we used brain-imaging data for gray matter in mm3 for the left and right frontal pole, the left and right superior frontal gyrus, the left and right medial frontal cortex, the left and right orbital frontal cortex, and the left and right frontal operculum, the left and right hippocampus, and the left and right thalamus. We also used brain-imaging data for total brain gray matter and white matter in mm3.

Toxoplasma gondii

The Toxoplasma gondii-related antibodies present in the UK Biobank were p22 and sag1 antibodies, measured in units of median florescence intensity [29]. The UK Biobank guidelines indicate a person is seropositive for Toxoplasma gondii if either the sag1 titer is greater than 160 or the p22 titer is greater than 100 (http://biobank.ndph.ox.ac.uk/showcase/field.cgi?tk=BVm2NA8JqLsnU55EBZF5XntyJ9AnSZMB1000738&id=23062). In statistical models, we included an indicator of Toxoplasma gondii seropositivity that was equal to 1 if participants were seropositive based on these criteria or 0 if they were negative. To capture any linear relationship between these antibodies and brain size, we independently examined the natural log of p22 and sag1 titers. We also examined the mean of standardized versions of natural-logged p22 and sag1 titers.

Covariates

To control for variables that potentially could confound associations between Toxoplasma gondii and brain volume, we adjusted our statistical models for several variables that have been associated with cognitive function [3032] or that plausibly could affect an association with brain volume, including age in years, sex (female, male), race/ethnicity (White, non-White), and educational attainment (having obtained a college degree compared to having obtained less than a college degree). Annual household income was originally recorded in five categories: (less than ₤18,000, ₤18,000 to ₤30,999, ₤31,000 to ₤51,999, ₤52,000 to ₤99,999, and greater than ₤100,000). We recoded responses to the middle value of each category, represented in ₤10,000 units (i.e. ₤18,000 to ₤30,999 became 2.45). We also included self-rated health (four-point scale ranging from poor to excellent), body-mass index (weight in kilograms/height in meters squared), smoking history (non-smoker, past, current), and frequency of alcohol use (six categories ranging from never to almost daily or daily). Statistical models of the five regions in the prefrontal cortex, hippocampus, and thalamus included an additional control of total brain volume, which was the volume of gray and white matter normalized for head size.

Statistical analysis

We estimated a series of models for each of the left and right brain regions (i.e., five prefrontal regions, the hippocampus, and the thalamus), with each model including a different focal independent variable (i.e. Toxoplasma gondii seropositivity, natural-log transformed sag1 antibodies, natural-log transformed p22 antibodies, and the mean of the standardized natural-log transformed sag1 and p22 antibodies). Each model included all covariates as well as total brain size. Subsequently, using these models as a baseline, we estimated additional models, each with a separate interaction of one measure of Toxoplasma gondii with age, sex, educational attainment, or race/ethnicity.

In total, this represents 56 statistical tests of interest in models without interactions and an additional 224 statistical tests for the interactions (i.e., 56 for each of four Toxoplasma gondii by control interactions). Consequently, to protect against alpha inflation due to multiple testing, we estimated a series of multivariate tests in which we tested a single independent variable and multiple dependent variables [33]. In doing this, we submitted all models where Toxoplasma gondii seropositivity was the focal independent variable in the absence of interactions (see Table 2) to a multivariate test that encompassed the joint covariance between the independent variable (i.e., Toxoplasma gondii) and dependent variables (i.e., the combination of left and right brain region volumes). We did this using Stata’s suest command [34], which produces a single parameter vector for all of the models that takes into account the joint covariance of the dependent variables and therefore allows a test whose null hypothesis is that the joint relationship between the predictor and the dependent variables is zero. If the multivariate test was not significant, we did not consider any significant individual test to be significant. Conversely, if the multivariate test was significant, we concluded that any significant individual estimate was indeed valid.

Table 2. Relationship between Toxoplasma gondii and prefrontal brain volume (mm3): Unstandardized coefficients and 95% confidence intervals from linear regressiona.

Frontal
Pole Superior gyrus Medial cortex Orbital cortex Operculum cortex Hippocampus Thalamus Multivariate p
Seropositive .063
 Left -403.87 -103.53 -34.68 -10.40 -10.31 -103.62 75.98
-974.50,166.76 -465.60,258.54 -108.69,39.34 -191.75,170.94 -65.01,44.40 -211.35,4.11 -58.18,210.15
 Right -339.43 -312.21 -24.90 63.28 -33.86 -69.67 52.47
-961.72,282.85 -664.64,40.22 -100.23,50.43 -90.92,217.48 -88.12,20.41 -178.78,39.45 -77.82,182.76
ln(p22) .078
 Left -82.80 -11.56 -.63 -18.43 2.55 -27.44 33.24
-268.26,102.66 -129.10,105.97 -24.67,23.42 -77.25,40.38 -15.20,20.30 -62.46,7.57 -10.24,76.71
 Right -90.88 -80.15 3.14 21.50 -7.25 -8.38 24.34
-292.91,111.15 -194.69,34.39 -21.31,27.60 -28.53,71.54 -24.88,10.38 -43.85,27.09 -17.90,66.58
ln(sag1) .163
 Left -151.30 21.44 -6.94 -26.92 .72 -21.94 33.88
-396.65,94.05 -134.19,177.07 -38.77,24.89 -104.79,50.96 -22.79,24.23 -68.40,24.52 -23.77,91.52
 Right -54.08 -60.81 14.28 4.74 5.48 -27.42 23.98
-321.83,213.68 -212.75,91.12 -18.08,46.63 -61.57,71.06 -17.88,28.84 -74.32,19.49 -32.00,79.96
Mean of ln(p22) & ln(sag1) .124
 Left -159.89 4.46 -4.86 -31.34 2.44 -35.24 47.28
-429.14,109.36 -166.32,175.24 -39.79,30.08 -116.78,54.11 -23.35,28.24 -86.15,15.67 -15.90,110.45
 Right -105.00 -100.87 11.44 19.78 -2.21 -23.80 34.10
-398.66,188.65 -267.39,65.66 -24.08,46.96 -52.96,92.51 -27.85,23.42 -75.30,27.70 -27.28,95.49

Note:

a Each coefficient and associated confidence interval is from a different model that includes controls for age, sex, race, educational attainment, household income, self-rated health, body-mass index, smoking status, drinking frequency.

^b Multivariate tests test the multivariate significance of each pollutant on all of the brain volume outcomes. N = 385. Source: UK Biobank. * p < .05. ** p < .01. *** p < .001.

In a second set of analyses, we estimated a series of models of total gray-matter and total white-matter volume for the seropositivity, p22, sag1, and mean of p22 and sag1 variables. We also estimated subsequent models, each with an interaction term of each of the measures of Toxoplasma gondii with age, sex, educational attainment, and income. Although there were far fewer models in the second set of analyses compared to the first, we again estimated multivariate tests to protect against type-1 errors due to multiple testing [33].

We used Stata 16.1 (StataCorp, Stata Statistical Software, Release 16. College Station, Texas) for all analyses.

Results

The average age of the sample was 62.02 years, and 55 percent of the sample were women. Fifty-three percent of the sample had attained a college degree, and 96 percent were White. Twenty-six percent of the sample were seropositive for Toxoplasma gondii (Table 1). Table 1 also shows means, standard deviations (for continuous variables), and minimum and maximum values for all demographic, brain imaging, and Toxoplasma gondii variables that we included in the statistical models. By visual inspection, the prefrontal, hippocampal, and thalamic brain regions and the total gray-matter and total-white matter volumes were normally distributed.

Table 1. Descriptive statistics of study variables.

Mean SD Minimum Maximum
Prefrontal brain volume (mm3)
 Pole (left) 23449.58 2861.91 16896.00 33728.60
 Pole (right) 26515.12 3158.09 18330.40 36951.10
 Superior gyrus (left) 11118.54 1689.33 6940.39 17040.00
 Superior gyrus (right) 9700.46 1599.00 5946.68 15202.90
 Medial cortex (left) 1914.28 334.54 1137.32 2934.77
 Medial cortex (right) 1923.88 341.08 1121.24 3296.26
 Orbital cortex (left) 6678.90 882.68 4417.84 10268.60
 Orbital cortex (right) 6026.93 776.97 4045.75 8493.09
 Operculum cortex (left) 1507.08 256.05 805.67 2357.56
 Operculum cortex (right) 1351.52 250.79 630.69 2145.18
Hippocampus volume (mm3)
 Hippocampus (left) 3800.28 500.21 1811.00 5287.00
 Hippocampus (right) 3906.89 502.13 2332.00 5163.00
Thalamus volume (mm3)
 Thalamus (left) 7780.30 750.59 5499.00 9896.00
 Thalamus (right) 7592.70 729.83 5254.00 9566.00
Total brain volume (mm3) 1508803.82 73428.04 1299110.00 1700560.00
 Gray matter 800991.22 47779.65 672942.00 919510.00
 White matter 707812.52 40316.62 598262.00 830308.00
Toxoplasma gondii
 Seropositive .26 .00 1.00
 ln(p22) 3.34 1.37 .00 8.88
 ln(sag1) 4.39 1.04 .00 6.70
 Mean of ln(p22) & ln(sag1) -.06 .94 -3.59 2.28
Age 62.02 7.42 47.00 78.00
Female .55 .00 1.00
White .96 .00 1.00
College degree .53 .00 1.00
Income (in 10,000 ₤) 4.43 .90 12.50
Overall health 2.98 .67 1.00 4.00
Body-mass index 26.26 4.20 16.68 46.88
Smoking status
 Non-smoker .63 .00 1.00
 Past .34 .00 1.00
 Current .03 .00 1.00
Drinking frequency
 Daily or almost daily .18 .00 1.00
 3–4 times/week .25 .00 1.00
 Once or twice/week .27 .00 1.00
 1–3 times/month .12 .00 1.00
 Special occasions .13 .00 1.00
 Never .04 .00 1.00

Note: N = 385. Source: UK Biobank.

There were no significant associations between any of the measures of Toxoplasma gondii serology and prefrontal, hippocampal, or thalamic volumes (Table 2). Because of the uniform absence of statistically significant relationships in these analyses, we considered whether the analyses were underpowered because of the small sample size. Accordingly, we estimated post-hoc power analyses for each model to determine the sample size needed to identify a statistically significant result. We anticipated a biologically and clinically meaningful effect size to be close to the size of brain volume change typical for a one-year increase in aging [35]. The power analysis compared the model R2 of the model reported in Table 2 (i.e., a "full" model) with a "reduced" model that excluded age. The results of these comparisons are the sample sizes that would be needed to identify a statistically significant coefficient for age with 80-percent power and an alpha of .05.

The power analyses (Table 3) showed that our sample of 385 individuals did contain enough power to identify a significant effect with 80-percent power and an alpha of .05 for Toxoplasma gondii if the effect were as large as the age effect for the left frontal pole, the left and right orbital frontal cortex, the left frontal operculum, the left hippocampus, and the left and right thalamus. However, the analyses for the right frontal pole, the left and right superior frontal gyrus, the left and right medial frontal cortex, the right frontal operculum, and the right hippocampus were underpowered. The sample size estimates for the superior frontal gyrus were substantial. This suggests that age was not a useful variable to assess the power of our statistical model of superior frontal gyrus volumes.

Table 3. Power analyses: Required sample size for age effect on brain size to be significant.

Frontal
Pole Superior gyrus Medial cortex Orbital cortex Operculum cortex Hippocampus Thalamus
Seropositive
 Left 244 32315 501 170 275 386 141
 Right 628 5769494 495 120 840 2626 169
ln(p22)
 Left 231 26567 495 166 280 341 152
 Right 574 126582 503 126 759 2315 181
ln(sag1)
 Left 240 29333 493 170 273 377 142
 Right 615 9458555 486 121 815 2499 171
Mean of ln(p22) & ln(sag1)
 Left 232 30084 488 167 276 358 147
 Right 596 464343 502 122 811 2294 175

Note: N = 385. Source: UK Biobank.

Table 4 presents the p-value of the multivariate tests of interaction terms in models examining whether age, sex, education, or income, moderate the relationship of Toxoplasma gondii and the five regions in the prefrontal cortex, the hippocampus, and the thalamus. The results indicate significant multivariate interactions between the four Toxoplasma gondii variables and age as well as between Toxoplasma gondii seropositivity and education.

Table 4. Multivariate p-values from adjusted modelsa of the interactions of Toxoplasma gondii of the five left and right prefrontal regions, the left and right hippocampus, and the left and right thalamus with age, sex, education, and income.

T. gondii seropositive ln(p22) ln(sag1) Mean of ln(p22) & ln(sag1)
Age x T. gondii .016 .002 .049 .005
Female x T. gondii .546 .441 .119 .605
College degree x T. gondii .020 .189 .132 .086
Income x T. gondii .167 .242 .346 .220

Note:

a Each p-value represents a multivariate test which is a test of the null hypothesis considered within the joint covariance of the dependent variables (i.e., the left and right side of the five prefrontal regions, the hippocampus, and thalamus) and the respective interaction between one of the T. gondii variables and a predictor (e.g., Age x T. gondii seropositive).

Results of the corresponding univariate statistical tests of these sixteen multivariate tests are presented in S1 through S4 Tables in S1 File. N = 385. Source: UK Biobank.

The model-specific results presented in S1 through S4 Tables in S1 File indicate that none of the univariate interactions between Toxoplasma gondii and age was significant. Of the 224 interaction terms from adjusted models represented in the S1 File, only the interactions between Toxoplasma gondii seropositivity and educational attainment associated with gray-matter volume in the left superior frontal gyrus and in the left thalamus were statistically significant (S3 Table in S1 File). These two significant interactions represent less than one percent of the interaction models estimated. Therefore, although the associated multivariate test was significant (p = .020), the preponderance of evidence suggests that the relationship between Toxoplasma gondii and these brain volume regions does not vary by age, sex, education, or income.

In contrast to the findings for associations between the measures for Toxoplasma gondii infection and prefrontal, hippocampal, and thalamic gray-matter volumes, Table 5 shows that the natural-log transformed p22 antibody titers (b = -3960, 95-percent confidence interval, -6536 to -1383, p < .01) and the natural-log transformed sag1 antibody titers (b = -4863, 95-percent confidence interval, –8301 to -1425, p < .01) were associated with smaller total gray-matter volume, as was the mean of natural-log transformed p22 and sag1 titers (b = -6141, 95-percent confidence interval, -9886 to -2397, p < .01). There were no significant associations between any of the measures of Toxoplasma gondii infection and total white-matter volume.

Table 5. Relationship between Toxoplasma gondii and total brain volume (mm3): Unstandardized coefficients and 95% confidence intervals from linear regressiona.

Gray Matter White Matter Multivariate p
b 95%CI b 95%CI
Seropositive -6074 -14155,2007 583 -8217,9382 .295
ln(p22) -3960** -6536,-1383 -1828 -4654,998 .008
ln(sag1) -4863** -8301,-1425 92 -3679,3864 .014
Mean of ln(p22) & ln(sag1) -6141** -9886,-2397 -1375 -5495,2746 .004

Note:

a Each coefficient and associated confidence interval is from a different model that includes controls for age, sex, race, education, income, self-rated health, body-mass index, smoking status, drinking frequency.

N = 385. Source: UK Biobank.

* p < .05.

** p < .01.

*** p < .001.

Table 6 presents results of the multivariate tests of the interaction of Toxoplasma gondii with age, sex, education, and income with total gray-matter and total white-matter volumes as the dependent variables (individual models are presented in S5 Table in S1 File). Interactions between Toxoplasma gondii seropositivity and sex and between Toxoplasma gondii (all four measures) and income were associated with total gray-matter and total white-matter volumes. Out of 32 interaction models, seven were statistically significant, each of which withstood multivariable testing for multiple comparisons.

Table 6. Multivariate p-values from adjusted modelsa of the interactions of Toxoplasma gondii of total brain gray-matter volume and total brain white-matter volume with age, sex, education, and income.

T. gondii seropositive ln(p22) ln(sag1) Mean of ln(p22) & ln(sag1)
Age x T. gondii .203 .419 .089 .154
Female x T. gondii .022 .255 .877 .663
College degree x T. gondii .232 .137 .503 .285
Income x T. gondii .010 .007 .006 .003

Note:

a Each p-value represents a multivariate test which is a test of the null hypothesis considered within the joint covariance of the dependent variables (i.e., total brain gray-matter and white-matter volumes) and the respective interaction between one of the T. gondii variables and a predictor (e.g., Age x T. gondii seropositive).

Results of the corresponding univariate statistical tests for total brain gray matter and white matter that are represented in these multivariate tests are presented in S5 Table in S1 File. N = 385. Source: UK Biobank.

Discussion

The main finding from this community-based sample of middle-aged and late-middle-aged adults in the United Kingdom is an association between Toxoplasma gondii serointensity and smaller total gray-matter volume but no associations with total white-matter volume. Further, there were no associations between Toxoplasma gondii seropositivity and serointensity and gray-matter volume in five regions of the prefrontal cortex we evaluated, the hippocampus, and the thalamus.

The finding of a negative association between Toxoplasma gondii and total gray-matter volume suggests that changes (i.e., reductions) in gray-matter volume could be a mechanism of the relationship between Toxoplasma gondii and previously reported evidence of abnormal brain function, including worse cognitive functioning. While the smaller total gray-matter volume associated with Toxoplasma gondii serointensity could be a mechanism by which Toxoplasma gondii influences brain and cognitive function, we did not find that gray-matter volume in five different prefrontal regions, the hippocampus, or the thalamus was associated with either Toxoplasma gondii seropositivity or serointensity. Therefore, to the extent that reductions in gray-matter volume could be a mechanism of the relationship between Toxoplasma gondii and brain and cognitive functioning based on the association between Toxoplasma gondii and total gray-matter volume, the locale of the effect may be in brain regions we could not explore here, or a diffuse loss of gray matter might be associated with the decrease in brain and cognitive function associated with Toxoplasma gondii that some previous studies [814] have found. Further, even if reductions in brain volume is a mechanism of the relationship between Toxoplasma gondii and brain and cognitive functioning, other mechanisms could operate as well.

Few previous studies have investigated associations between Toxoplasma gondii serointensity and seropositivity and brain volume. Our results, however, are consistent with a previous study that found increased ventricular volume in mice infected with Toxoplasma gondii [24] and somewhat consistent with those of one previous study that found an association between Toxoplasma gondii and gray-matter density in schizophrenia, although they differ from other findings from the latter study that showed no association between gray-matter density and toxoplasmosis in healthy controls [25]. Possible reasons for these differences could be due to different samples, different control variables, and differences in statistical power, as the previous study included only 56 healthy controls of whom only 13 were infected with Toxoplasma gondii, [25] and might have been underpowered to detect associations between Toxoplasma gondii and brain volume in the healthy control group.

We found no meaningful interactions between Toxoplasma gondii and age, sex, educational attainment, and income associated with gray-matter volume in the five regions of the prefrontal cortex, the hippocampus, and the thalamus. Because only 2 out of 224 interaction models (less than one percent) were significant, the overwhelming pattern in this set of results suggests that there were no statistically significant interactions. In contrast, seven out of 32 (22 percent) interactions between Toxoplasma gondii and sex and between Toxoplasma gondii and income were significantly associated with total gray-matter and total white-matter volumes even after multivariate correction for multiple testing. There were significant interactions between Toxoplasma gondii seropositivity and sex and both total gray-matter and total white-matter volumes, between Toxoplasma gondii seropositivity and income and both total gray-matter and total white-matter volumes, between the natural-log transformed p22 titer and income and total white-matter volume, between the natural-log transformed sag1 titer and income and total white-matter volume, and between the mean of the natural-log transformed p22 and sag1 titers and income and total white-matter volume. Together, the significant interaction models associated with total gray-matter and total white-matter volumes suggest that sex and income might moderate associations between Toxoplasma gondii serointensity and total gray-matter and total white-matter volumes.

Based on the results of the regression modeling, every one-unit increase in the natural-log transformed p22 titer was associated with a 0.26 percent decrease in total gray-matter volume or a 1.31 percent decrease in total gray-matter volume for a five-unit increase in the natural-log transformed p22 titer. Similarly, every one-unit increase in the natural-log transformed sag1 titer was associated with a 0.32 percent decrease in total gray-matter volume or a 1.6 percent decrease in total gray-matter volume for every five-unit increase in the natural-log transformed sag1 titer. While small, the differences in gray-matter volume associated with a five-unit increase in p22 or sag1 titers is consistent with the amount of volume loss associated with one year of aging [35]. Nonetheless, the clinical significance of the association between Toxoplasma gondii and gray-matter volume is unknown. Further, because of limitations associated with the cross-sectional design of our study, it is unknown whether the smaller gray-matter volume associated with Toxoplasma gondii is static or progressive.

An important consideration regarding our findings showing no associations between Toxoplasma gondii and gray-matter volume in the prefrontal cortex, hippocampus, and thalamus is that of sample size. To better interpret these negative findings, we conducted post-hoc power analyses to show the sample size needed to detect an effect on gray-matter volume from one year of aging in elderly subjects, reasoning that this would be a meaningful effect size from Toxoplasma gondii. The results of these power analyses showed that our study had 80 percent power to detect an effect size equal to the size that previous studies have associated with the effect of one year of aging in older adults [35, 36] for the left frontal pole, the left and right orbital frontal cortex, the left frontal operculum, the left hippocampus, and the left and right thalamus but not for the right frontal pole, the left and right superior frontal gyrus, the left and right orbital frontal cortex, the right frontal operculum, and the right hippocampus. As such, based on our sample size, several of the analyses were underpowered, and, accordingly, we do not know if in the underpowered analyses that there was no association or whether the lack of a significant association was due to lack of power from small sample sizes. In the analyses that were adequately powered, we are more confident concluding that there was no association.

In addition to the small sample size of our study, several other factors require consideration when interpreting our findings. One is that in the analyses of the prefrontal region, the hippocampus, and the thalamus, we examined only gray matter and do not know whether Toxoplasma gondii could be associated with white-matter volume. Similarly, we did not investigate gray matter in other individual regions. Gray-matter volume in other brain regions could be vulnerable to Toxoplasma gondii. An additional consideration is whether different strains of Toxoplasma gondii could affect gray-matter volume, as different strains might differ in virulence [37]. The sample we used was from the United Kingdom, whereas Toxoplasma gondii strains in other regions could have different effects on gray-matter volume, and inadequate data currently address this issue. Further, our study is cross sectional. In addition to not knowing whether the possible loss of total gray-matter volume associated with Toxoplasma gondii is progressive, we do not know when the initial infection from Toxoplasma gondii occurred. Infection during critical developmental periods could affect gray matter differently from infection during middle age or late middle age. The cross-sectional design also precludes definitive cause-and-effect determinations in the association between Toxoplasma gondii and total gray-matter volume. While we tested for several interactions, we did not test for interactions with other infectious diseases. It is feasible that interactions between Toxoplasma gondii and other infectious diseases could influence gray-matter volume. While we included several covariates in our models that potentially could confound the association between Toxoplasma gondii and brain volume, other variables that we did not include potentially could confound the association between Toxoplasma gondii and gray-matter volume, resulting in the possibility of residual confounding.

In conclusion, in this study of community-dwelling middle-aged and late middle-aged adults in the United Kingdom, Toxoplasma gondii serointensity was associated with total gray-matter volume but not with total white-matter volume. There were no associations between Toxoplasma gondii seropositivity and serointensity and gray-matter volume in the prefrontal cortex, the hippocampus, or the thalamus, although several of these analyses were underpowered. Together, these findings suggest that Toxoplasma gondii in humans might be associated with smaller total gray-matter volume, although whether there is progressive loss of gray-matter volume is unknown. Additional research investigating associations between Toxoplasma gondii and brain volume including in other regions of the world is needed.

Supporting information

S1 File

(DOCX)

Acknowledgments

This research has been conducted using the UK Biobank Resource under Application Number 41535. We also acknowledge the participants in the UK Biobank.

Data Availability

Data underlying the results can be obtained through application to the UK Biobank http://www.ukbiobank.ac.uk. These data belong to the UK Biobank. This research has been conducted using the UK Biobank Resource under Application Number 41535.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965–76. 10.1016/S0140-6736(04)16412-X [DOI] [PubMed] [Google Scholar]
  • 2.Severance EG, Xiao J, Jones-Brando L, Sabunciyan S, Li Y, Pletnikov M, et al. Toxoplasma gondii-A Gastrointestinal Pathogen Associated with Human Brain Diseases. Int Rev Neurobiol. 2016;131:143–63. 10.1016/bs.irn.2016.08.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Elmore SA, Jones JL, Conrad PA, Patton S, Lindsay DS, Dubey JP. Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends in parasitology. 2010;26(4):190–6. 10.1016/j.pt.2010.01.009 [DOI] [PubMed] [Google Scholar]
  • 4.Guenter W, Bielinski M, Deptula A, Zalas-Wiecek P, Piskunowicz M, Szwed K, et al. Does Toxoplasma gondii infection affect cognitive function? A case control study. Folia Parasitol (Praha). 2012;59(2):93–8. 10.14411/fp.2012.014 [DOI] [PubMed] [Google Scholar]
  • 5.Sugden K, Moffitt TE, Pinto L, Poulton R, Williams BS, Caspi A. Is Toxoplasma Gondii Infection Related to Brain and Behavior Impairments in Humans? Evidence from a Population-Representative Birth Cohort. PLoS One. 2016;11(2):e0148435 10.1371/journal.pone.0148435 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Torniainen-Holm M, Suvisaari J, Lindgren M, Harkanen T, Dickerson F, Yolken RH. The lack of association between herpes simplex virus 1 or Toxoplasma gondii infection and cognitive decline in the general population: An 11-year follow-up study. Brain Behav Immun. 2019;76:159–64. 10.1016/j.bbi.2018.11.016 [DOI] [PubMed] [Google Scholar]
  • 7.Stock AK, Heintschel von Heinegg E, Kohling HL, Beste C. Latent Toxoplasma gondii infection leads to improved action control. Brain Behav Immun. 2014;37:103–8. 10.1016/j.bbi.2013.11.004 [DOI] [PubMed] [Google Scholar]
  • 8.Beste C, Getzmann S, Gajewski PD, Golka K, Falkenstein M. Latent Toxoplasma gondii infection leads to deficits in goal-directed behavior in healthy elderly. Neurobiol Aging. 2014;35(5):1037–44. 10.1016/j.neurobiolaging.2013.11.012 [DOI] [PubMed] [Google Scholar]
  • 9.Gajewski PD, Falkenstein M, Hengstler JG, Golka K. Toxoplasma gondii impairs memory in infected seniors. Brain Behav Immun. 2014;36:193–9. 10.1016/j.bbi.2013.11.019 [DOI] [PubMed] [Google Scholar]
  • 10.Gale SD, Brown BL, Erickson LD, Berrett A, Hedges DW. Association between latent toxoplasmosis and cognition in adults: a cross-sectional study. Parasitology. 2015;142(4):557–65. 10.1017/S0031182014001577 [DOI] [PubMed] [Google Scholar]
  • 11.Mendy A, Vieira ER, Albatineh AN, Gasana J. Immediate rather than delayed memory impairment in older adults with latent toxoplasmosis. Brain Behav Immun. 2015;45:36–40. 10.1016/j.bbi.2014.12.006 [DOI] [PubMed] [Google Scholar]
  • 12.Nimgaonkar VL, Yolken RH, Wang T, Chang CC, McClain L, McDade E, et al. Temporal Cognitive Decline Associated With Exposure to Infectious Agents in a Population-based, Aging Cohort. Alzheimer Dis Assoc Disord. 2016;30(3):216–22. 10.1097/WAD.0000000000000133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Pearce BD, Kruszon-Moran D, Jones JL. The association of Toxoplasma gondii infection with neurocognitive deficits in a population-based analysis. Soc Psychiatry Psychiatr Epidemiol. 2014;49(6):1001–10. 10.1007/s00127-014-0820-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Rossini JC, Lopes CS, Dirscherl FP, Silva DA, Mineo JR. Altered visual attention behavior of Toxoplasma gondii-infected individuals. Psychol Neurosci. 2019;12(4):485–94. [Google Scholar]
  • 15.Gale SD, Erickson LD, Thacker EL, Mitchell EL, Brown BL, Hedges DW. Toxoplasma gondii seropositivity and serointensity and cognitive function in adults. PLoS Negl Trop Dis. 2020;14(10):e0008733 10.1371/journal.pntd.0008733 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bayani M, Riahi SM, Bazrafshan N, Ray Gamble H, Rostami A. Toxoplasma gondii infection and risk of Parkinson and Alzheimer diseases: A systematic review and meta-analysis on observational studies. Acta Trop. 2019;196:165–71. 10.1016/j.actatropica.2019.05.015 [DOI] [PubMed] [Google Scholar]
  • 17.Ngoungou EB, Bhalla D, Nzoghe A, Darde ML, Preux PM. Toxoplasmosis and epilepsy--systematic review and meta analysis. PLoS Negl Trop Dis. 2015;9(2):e0003525 10.1371/journal.pntd.0003525 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Gajewski PD, Falkenstein M, Hengstler JG, Golka K. Reduced ERPs and theta oscillations underlie working memory deficits in Toxoplasma gondii infected seniors. Biol Psychol. 2016;120:35–45. 10.1016/j.biopsycho.2016.08.002 [DOI] [PubMed] [Google Scholar]
  • 19.Berenreiterova M, Flegr J, Kubena AA, Nemec P. The distribution of Toxoplasma gondii cysts in the brain of a mouse with latent toxoplasmosis: implications for the behavioral manipulation hypothesis. PLoS One. 2011;6(12):e28925 10.1371/journal.pone.0028925 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Xiao J, Yolken RH. Strain hypothesis of Toxoplasma gondii infection on the outcome of human diseases. Acta physiologica. 2015;213(4):828–45. 10.1111/apha.12458 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Xiao J, Kannan G, Jones-Brando L, Brannock C, Krasnova IN, Cadet JL, et al. Sex-specific changes in gene expression and behavior induced by chronic Toxoplasma infection in mice. Neuroscience. 2012;206:39–48. 10.1016/j.neuroscience.2011.12.051 [DOI] [PubMed] [Google Scholar]
  • 22.Pietschnig J, Penke L, Wicherts JM, Zeiler M, Voracek M. Meta-analysis of associations between human brain volume and intelligence differences: How strong are they and what do they mean? Neurosci Biobehav Rev. 2015;57:411–32. 10.1016/j.neubiorev.2015.09.017 [DOI] [PubMed] [Google Scholar]
  • 23.Royle NA, Booth T, Valdes Hernandez MC, Penke L, Murray C, Gow AJ, et al. Estimated maximal and current brain volume predict cognitive ability in old age. Neurobiol Aging. 2013;34(12):2726–33. 10.1016/j.neurobiolaging.2013.05.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hermes G, Ajioka JW, Kelly KA, Mui E, Roberts F, Kasza K, et al. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation. 2008;5:48 10.1186/1742-2094-5-48 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Horacek J, Flegr J, Tintera J, Verebova K, Spaniel F, Novak T, et al. Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: voxel-based-morphometry (VBM) study. World J Biol Psychiatry. 2012;13(7):501–9. 10.3109/15622975.2011.573809 [DOI] [PubMed] [Google Scholar]
  • 26.Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779 10.1371/journal.pmed.1001779 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Alfaro-Almagro F, Jenkinson M, Bangerter NK, Andersson JLR, Griffanti L, Douaud G, et al. Image processing and Quality Control for the first 10,000 brain imaging datasets from UK Biobank. Neuroimage. 2018;166:400–24. 10.1016/j.neuroimage.2017.10.034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Miller K, Alfaro-Almagro F, Bangerter N, Thomas D, Yacoub E, Xu J, et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. Nat Neurosci. 2016;19(11):1523–36. 10.1038/nn.4393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Brenner N, Mentzer AJ, Butt J, Braband KL, Michel A, Jeffery K, et al. Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. PLoS One. 2019;14(1):e0210407 10.1371/journal.pone.0210407 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimer’s & dementia: the journal of the Alzheimer’s Association. 2015;11(6):718–26. 10.1016/j.jalz.2015.05.016 [DOI] [PubMed] [Google Scholar]
  • 31.Marden J, Tchetgen E, Kawachi I, Glymour M. Contribution of Socioeconomic Status at 3 Life-Course Periods to Late-Life Memory Function and Decline: Early and Late Predictors of Dementia Risk. Am J Epidemiol. 2017;186(7):805–14. 10.1093/aje/kwx155 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Szczepanski SM, Knight RT. Insights into human behavior from lesions to the prefrontal cortex. Neuron. 2014;83(5):1002–18. 10.1016/j.neuron.2014.08.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Rencher AC, Scott DT. Assessing the Contribution of Individual Variables Following Rejection of a Multivariate Hypothesis. Commun Stat Simulat. 1990;19(2):535–53. [Google Scholar]
  • 34.Mize TD, Doan L, Long JS. A general framework for comparing predictions and marginal effects across models. Sociological Methodology. 2019;49(1):152–89. [Google Scholar]
  • 35.Raz N, Lindenberger U, Rodrigue KM, Kennedy KM, Head D, Williamson A, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex. 2005;15(11):1676–89. 10.1093/cercor/bhi044 [DOI] [PubMed] [Google Scholar]
  • 36.Raz N, Gunning FM, Head D, Dupuis JH, McQuain J, Briggs SD, et al. Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. Cereb Cortex. 1997;7(3):268–82. 10.1093/cercor/7.3.268 [DOI] [PubMed] [Google Scholar]
  • 37.Darde ML. Toxoplasma gondii, "new" genotypes and virulence. Parasite. 2008;15(3):366–71. 10.1051/parasite/2008153366 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Niels Bergsland

18 Nov 2020

PONE-D-20-30012

Association between Toxoplasma gondii Seropositivity and Serointensity and Brain Volume in Adults: A Cross-Sectional Study

PLOS ONE

Dear Dr. Gale,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

In addition to the comments from the Reviewers, I see that “gender” is used throughout the manuscript, although "sex" is also used. Usually, “sex” (the biological designation) is meant. “Gender” is the social construct and is rarely relevant in the context of the current manuscript. Please revise the text to use “sex” rather than “gender” throughout.

Please submit your revised manuscript by Jan 02 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Niels Bergsland

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Associating Toxoplasma gondii to regional brain volume is an interesting research question. The authors used data available from UKBioBank to assess the relationship between serological data for exposure to Toxoplasma gondii and five prefrontal brain regions, the hippocampus and the thalamus.

This is a very well written manuscript.

The authors discuss "changes" due to Toxoplasma gondii however this is a cross-sectional study and the authors are only able to estimate "associations".

Brain volume is not directly associated with cognitive ability so this is unlikely to explain reductions in those that are seropositive.

Minor points:

Table 1 Income should be in £ not lb.

Reviewer #2: -Add the uniqueness of this study compared to other studies to discuss the same issue.

-Add more on the basis of this disease in the introduction

-Add shortly about routine MR imaging of brain in this disorder

-Add images of brain volume for patients and controls

Discus role of imaging using these refs

-Discuss the merits and limitations of the technique applied

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Gordon D. Waiter

Reviewer #2: Yes: Ahmed Abdel Khalek Abdel Razek MD

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 5;16(2):e0245994. doi: 10.1371/journal.pone.0245994.r002

Author response to Decision Letter 0


5 Jan 2021

Reviewer #1:

Associating Toxoplasma gondii to regional brain volume is an interesting research question. The authors used data available from UK BioBank to assess the relationship between serological data for exposure to Toxoplasma gondii and five prefrontal brain regions, the hippocampus and the thalamus. This is a very well written manuscript.

The authors discuss "changes" due to Toxoplasma gondii however this is a cross-sectional

study and the authors are only able to estimate "associations".

We fully agree that we can only estimate associations in this study. We have now either eliminated references to “changes” and have used “associations” instead or have made it clear that we mean association.

Brain volume is not directly associated with cognitive ability so this is unlikely to explain

reductions in those that are seropositive.

This is a really good point. There is evidence, though, that in healthy individuals, total brain volume does correlate with intelligence (see meta-analysis by Pietschnig et al., 2015), although the mechanism is unclear and the overall correlations while significant are small. In addition, there is evidence that brain volume in late life is associated with concurrent cognitive function (Royle NA, et al., 2013). We have added these references and clarified that we were looking for a potential mechanism by which Toxoplasma gondii could be associated with changes in brain function including cognition. As such, we now make an argument in the revised version of the manuscript that brain volume requires consideration in understanding how Toxoplasma gondii might affect brain and cognitive function.

Table 1 Income should be in £ not lb.

We have made this change.

Reviewer #2:

Add the uniqueness of this study compared to other studies to discuss the same issue.

We indicate in the introduction section that there are very few studies that have investigated the association between volumetric brain measurements and Toxoplasma gondii. The paper by Horacek et al. (2012) used a slightly different neuroimaging technique (VBM) than did the UK Biobank to compare controls with and without Toxoplasma gondii as well as those with schizophrenia who were either seropositive or seronegative. The sample size of the controls was only 56, of whom only 13 were seropositive for Toxoplasma gondii. Our use of a much larger sample size makes our study unique and less prone to error.

Add more on the basis of this disease in the introduction

We have added additional information about the biology and epidemiology of Toxoplasma gondii in the introduction section.

Add shortly about routine MR imaging of brain in this disorder

Routine MR imaging is not used clinically in latent toxoplasmosis. Further, few studies have investigated MR imaging in toxoplasmosis, and we have included in our paper the available studies that have used MR imaging in studying brain volume associated with Toxoplasma gondii.

Add images of brain volume for patients and controls

In our analyses, we used preprocessed MRI data made available by the UK Biobank and did not analyze the original MRI images ourselves. Although we recognize the intellectual value of presenting characteristic Toxoplasma gondii positive and negative brain images, the simple response to this request is that cannot because we do not have access to the images themselves. Furthermore, because we did not use the MRI images at any stage of our analyses, we feel that it could misrepresent the MRI data we did use as the product of our own analysis of the MRI images if we included images in our report. Please note that Table 1 contains data about brain volumes in the study sample.

Discus role of imaging using these refs

MRI imaging is not used clinically in latent toxoplasmosis, and few findings from studies investigating MR imaging in latent toxoplasmosis are available. Our study is one of the few available studies reporting abnormalities in brain imaging of latent toxoplasmosis. As such, there is not enough information about the role of imaging in latent toxoplasmosis. Based on the findings currently available, we believe that the best we can do is to write as we have that additional research is required to better understand the associations between Toxoplasma gondii and brain volume.

Discuss the merits and limitations of the technique applied

As discussed in the discussion section and other sections of the manuscript, we acknowledge the following merits: utilization of a large dataset, standardized automated neuroimaging methods, statistical adjustment for variables known to be associated with brain volume (age, sex, education etc.), and validated cognitive measures were all strengths of this study. We described the limitations including decreased power in some analyses, the inability to know when a given participant initially acquired the infection, focusing on gray-matter volume in prefrontal regions when white-matter pathways could have been affected in prefrontal regions, the potential difference that different strains of Toxoplasma gondii may be related to, and the fact that our subjects were in the middle age to late age range. These were all limitations. In the revised manuscript, we have added material about the potential for residual confounding and also mention that the cross-sectional design precludes determination of causal relationships. While presentation of potential weaknesses of our study is not necessarily exhaustive, we fell that it identifies what we think are critical issues that readers should be aware of as they read the results of the paper.

Decision Letter 1

Niels Bergsland

12 Jan 2021

Association between Toxoplasma gondii Seropositivity and Serointensity and Brain Volume in Adults: A Cross-Sectional Study

PONE-D-20-30012R1

Dear Dr. Gale,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Niels Bergsland

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Niels Bergsland

14 Jan 2021

PONE-D-20-30012R1

Association between Toxoplasma gondii Seropositivity and Serointensity and Brain Volume in Adults: A Cross-Sectional Study

Dear Dr. Gale:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Niels Bergsland

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (DOCX)

    Data Availability Statement

    Data underlying the results can be obtained through application to the UK Biobank http://www.ukbiobank.ac.uk. These data belong to the UK Biobank. This research has been conducted using the UK Biobank Resource under Application Number 41535.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES